Physician profile
Mary Ulrich
NPI 1811997539
$2,028.80
in general payments reported to CMS, 2019-2025
18 companies · $275 in 2025
The $275 reported for 2025 was more than what 82% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $44.47 · 2021: $181 · 2022: $245 · 2023: $570 · 2024: $503 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,347.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $353.94 | 2022-2025 | Azstarys |
| Tris Pharma INC | $281.06 | 2019-2025 | Dyanavel Xr |
| Sanofi-Aventis U.S. LLC | $272.57 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $185.97 | 2019-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Supernus Pharmaceuticals, INC. | $177.44 | 2023-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $164.97 | 2019-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $123.90 | 2019-2024 | Bexsero, Pediarix, Menveo |
| Cranial Technologies, INC | $98.79 | 2019-2024 | Doc Band |
| Neos Therapeutics, LP | $83.93 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.92 | 2020-2022 | |
| Sanofi Pasteur INC. | $48.73 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $46.79 | 2023-2024 | Flumist Quadrivalent |
| Seqirus USA INC | $39.88 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
| Ultragenyx Pharmaceutical INC. | $28.36 | 2021 | |
| Alk-Abello, INC | $19.10 | 2025 | Neffy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.97 | 2023 | |
| Phadia US INC. | $17.83 | 2024 | Immunocap |
| Azurity Pharmaceuticals, INC. | $16.65 | 2025 | Alvesco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Ulrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.